[Efficacy and safety of telithromycin in the treatment of acute maxillary sinusitis].

The aim of this study was to evaluate the efficacy and tolerance of 5 days of telithromycin (800 mg once a day) in the treatment of bacteriologically proven acute maxillary sinusitis (AMS).
Two hundred and sixty-three patients with a clinically diagnosed AMS and purulent rhinorrhea were included in this prospective, multicenter, non-comparative open-labeled French study. Pus was sampled from the middle meatus before inclusion. The bacterial origin of the infection was confirmed by a scientific committee (presence of leucocytes/bacteria on direct microscopic examination of pus, and positive culture).
Seven to 14 days after the end of the treatment the clinical success rate (cure and improvement) was 91% (63/69 patients) in the per protocol bacteriologically documented (PPb) population and 90% (231/257 patients) in the modified intent-to-treat population. The main strains identified in the 69 patients of PPb population were Streptococcus pneumoniae (47.8%, of which 15 strains with reduced susceptibility to penicillin and 15 erythromycin resistant strains), Haemophilus influenzae (14.5%), Branhamella catarrhalis (8.7%) and Streptococcus aureus (29.0%). Drug tolerance was assessed on 263 patients as satisfactory with mainly gastro-intestinal disorders considered to be related to the treatment in 7.6% of patients. No serious adverse event related to the study drug was reported.
The efficacy of telithromycin 800 mg once daily for 5 days is confirmed in the treatment of AMS, even for those due to S. Pneumoniae.
AuthorsC Dubreuil, D Ebbo, F Goldstein,
JournalMeĢdecine et maladies infectieuses (Med Mal Infect) Vol. 35 Issue 4 Pg. 197-204 (Apr 2005) ISSN: 0399-077X [Print] France
Vernacular TitleEfficacité et tolérance de la télithromycine dans le traitement des sinusites maxillaires aiguës.
PMID15914288 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)
Chemical References
  • Anti-Bacterial Agents
  • Ketolides
  • telithromycin
  • Acute Disease
  • Adult
  • Anti-Bacterial Agents (therapeutic use)
  • Bacterial Infections (classification, drug therapy)
  • Female
  • France
  • Humans
  • Ketolides (therapeutic use)
  • Male
  • Maxillary Sinusitis (drug therapy)
  • Recurrence
  • Reproducibility of Results
  • Safety

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: